Cilostazol Has Beneficial Effects in Treatment of Intermittent Claudication Results from a Multicenter, Randomized, Prospective, Double-blind Trial.

Dawson, David L.; Cutler, Bruce S.; Meissner, Mark H.; Strandness, Eugene

doi:10.1097/01823246-199809040-00008

Cited by 110 publications

(152 citation statements)

References 0 publications

Supporting

Mentioning

150

Contrasting

Unclassified

Order By: Relevance

“…Cilostazol was used in this study, because of the ability to inhibit the primary and secondary platelet aggregation induced by a variety of stimuli including adenosine diphosphate, thrombin, collagen, arachidonic acid and shear stress [24,25]. Cilostazol is also approved by the US Food and Drug Administration for use in treating intermittent claudication [40]. These advantages made Cilostazol a suitable candidate for an encapsulation into liposomes.…”

Section: Discussionmentioning

confidence: 99%

Inhibition of metastasis in a murine 4T1 breast cancer model by liposomes preventing tumor cell-platelet interactions

Wenzel

Zeisig

Fichtner

2009

Clin Exp Metastasis

View full text Add to dashboard Cite

The interaction between circulating tumor cells and blood components, mainly platelets, plays an important role during metastasis. In this study, we prepared liposomes containing the platelet aggregation inhibitor Cilostazol (Cil-L). The objective of this study was to investigate the effect of this Cil-L on platelet aggregation and complex formation with murine 4T1 breast cancer cells in vitro and to determine their anti-metastatic potency in a spontaneous metastasis model of 4T1 breast cancer. Cil-L significantly inhibited the aggregation of platelets by up to 78% and completely abolished the complex formation of 4T1 tumor cells in the presence of activated platelets in vitro. Intravenous (i.v.) injection of Cil-L into mice significantly reduced the aggregability of mouse platelets by 60% measured ex vivo. To gain deeper insight into the mode of metastasis formation in a spontaneous metastasis model, 4T1 breast cancer cells were transplanted into the mammary fad pad of mice and metastasis to the mouse lungs was investigated with regard to tumor cell settlement and metastatic growth. We could demonstrate that the formation of pulmonary metastases was significantly reduced by 55% when mice were treated intravenously with 100 nmol Cil-L 6 h before tumor cell inoculation and then daily for 2 weeks. We conclude that Cil-L reduced metastasis by restricting the aggregability of mouse platelets, which probably prevents the interaction between circulating 4T1 tumor cells and platelets, making the Cil-L a useful tool for the inhibition of breast cancer metastasis in mice.

show abstract

Section: Discussionmentioning

confidence: 99%

Inhibition of metastasis in a murine 4T1 breast cancer model by liposomes preventing tumor cell-platelet interactions

Wenzel

Zeisig

Fichtner

2009

Clin Exp Metastasis

View full text Add to dashboard Cite

show abstract

“…With antiplatelet and vasodilator properties, cilostazol is indicated for the treatment of intermittent claudication. 24,25 Cilostazol inhibits vascular smooth muscle proliferation and causes vasodilatation. Cilostazol improves both pain-free and maximal treadmill walking distance.…”

Section: Discussionmentioning

confidence: 99%

Process of Care and Outcomes in Patients with Peripheral Arterial Disease

et al. 2007

View full text Add to dashboard Cite

Our data suggest that glucose control is key to reducing the risk for adverse outcomes, particularly limb events in African Americans. Certain process of care measures, as markers of disease severity and disease management, are associated with poor outcomes in patients with PAD. Further work is needed to determine the role of early disease intervention to reduce poor outcomes in patients with PAD.

show abstract

“…5,6 Intracellular cAMP blocks the release of calcium ions from intracellular storage granules within the smooth muscle cells, thereby inhibiting the function of contractile proteins. Recent prospective and randomized clinical trials have demonstrated that cilostazol is safe and is tolerated well in the treatment of intermittent claudication, 16 and that it significantly reduces restenosis and target lesion revascularization rates after successful percutaneous transluminal coronary angioplasty. 17 In addition to its antiplatelet and vasodilator effects, several animal studies have suggested that cilostazol may also inhibit endothelial cell death and promote growth.…”

Section: Discussionmentioning

confidence: 99%

Effect of Cilostazol on Endothelial Cell Denudation and Proliferation in Canine Vein Grafts

et al. 2001

View full text Add to dashboard Cite

The purpose of the present study was to examine the effects of cilostazol on endothelial cell denudation and proliferation in vein grafts used as arterial substitutes. Unilateral aortoiliac bypass was performed using the lateral jugular vein in 20 mongrel dogs. The animals were divided into two groups according to whether or not cilostazol was given. The grafts were removed at intervals of 1 day and 50 days, and the luminal surface was assessed for endothelial cell coverage (%). The denudation of endothelial cells was less extensive in the cilostazol group than in the control group on postoperative day 1. There was significantly more proliferation of endothelial cells in the control group over the course of time than in the cilostazol group. In conclusion, cilostazol significantly prevented early endothelial cell denudation, although it did not appear to stimulate successive endothelial cell proliferation. Therefore, cilostazol may help preserve an intact intima, which would potentially result in the inhibition of intimal hyperplasia.

show abstract

Cilostazol Has Beneficial Effects in Treatment of Intermittent Claudication Results from a Multicenter, Randomized, Prospective, Double-blind Trial.

Cited by 110 publications

References 0 publications

Inhibition of metastasis in a murine 4T1 breast cancer model by liposomes preventing tumor cell-platelet interactions

Inhibition of metastasis in a murine 4T1 breast cancer model by liposomes preventing tumor cell-platelet interactions

Process of Care and Outcomes in Patients with Peripheral Arterial Disease

Effect of Cilostazol on Endothelial Cell Denudation and Proliferation in Canine Vein Grafts

Contact Info

Product

Resources

About